Trial Profile
An Open Label Sequential Dose Response Observational Study of Intravitreally Administered Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Fibrinolysin human (Primary)
- Indications Eye disorders
- Focus Therapeutic Use
- Sponsors Bausch & Lomb
- 11 Dec 2014 New trial record